Notes

The company that issues CNXC, specifically CNXC91106, announced on September 15, 2023, that it will release its earnings on September 27, 2023, after the market closes, which is called AMC, or after market close. The main source of this information is the company itself, which scheduled its own release, and it was also copied by GlobeNewswire, but this copy is not an independent confirmation, it is just the company's announcement being shared. This information was found on September 11, 2026, through a browser search, and it is based on the original announcement. The scheduled date is the old, or vintage, date, and it does not prove that there was no other important news before, so the entire event session should be excluded. https://ir.concentrix.com/news/news-details/2023/Concentrix-Provides-Update-on-Pending-Combination-with-Webhelp-Schedules-Release-of-Fiscal-Third-Quarter-2023-Financial-Results-and-Webcast-of-Investor-Conference-Call-09-15-2023/default.aspx

A company that issues stocks, called CNXC, with the code CNXC91106, announced on June 14, 2023, that it will release its primary advance earnings, which are its main profits, on June 28, 2023, after the market closes, known as AMC, or after-market close. The closest source of this information is the company itself, which scheduled its own release. A copy of this announcement can also be found on GlobeNewswire, but this is just a copy distributed by the company, not a separate confirmation. This information was found on September 11, 2026, through a browser search. The scheduled date is based on old information and does not guarantee that there was no other important news before this date. The entire event session should be excluded. https://www.globenewswire.com/news-release/2023/6/14/2688332/0/en/concentrix-schedules-release-of-fiscal-second-quarter-2023-financial-results-and-webcast-of-investor-conference-call.html

The company CNXC announced on 2023-03-13 that it will release its earnings on 2023-03-29 after the market closes, which is known as AMC, or after market close, a time when trading has ended for the day. The information comes directly from the company, which scheduled its own release, and was also found on GlobeNewswire, although this is just a copy of the company's announcement, not an independent confirmation. This information was found on 2026-09-11 through a browser search. The scheduled date is based on old information from 2023, and does not guarantee that there was no other important news before this date, so the entire event session will be excluded. https://ir.concentrix.com/news/news-details/2023/Concentrix-Schedules-Release-of-Fiscal-First-Quarter-2023-Financial-Results-and-Webcast-of-Investor-Conference-Call-03-13-2023/default.aspx

A company announcement was made on December 22, 2022, stating that the earnings release for CNXC91106 would be on January 19, 2023, after the market closes. The information was found on GlobeNewswire, which was a copy of the company's own release, not an independent confirmation. This information was retrieved on September 11, 2026, through a browser search. The scheduled date is based on old information and does not guarantee that there was no other important news before this date, so the entire event session will be excluded. https://ir.concentrix.com/news/news-details/2022/Concentrix-Schedules-Release-of-Fourth-Quarter-and-Full-Year-Fiscal-2022-Financial-Results-and-Webcast-of-Investor-Conference-Call-12-22-2022/default.aspx

A company announcement was made on 2022-09-01, with the earnings release scheduled for 2022-09-28 after the market closes, which is known as AMC, or after market close, a time when the market is not trading. The information came directly from the company, which scheduled its own release, and was also found on GlobeNewswire, which was distributing the company's announcement, not confirming it independently. This information was found on 2026-09-11 through a browser search of the original source. The scheduled date is based on old information from 2022, and does not guarantee that there was no other important news before then, so the entire event session will be excluded. https://ir.concentrix.com/news/news-details/2022/Concentrix-Schedules-Release-of-Fiscal-Third-Quarter-2022-Financial-Results-and-Webcast-of-Investor-Conference-Call-09-01-2022/default.aspx

The company CNXC announced on 2022-05-31 that it will release its earnings on 2022-06-27 after the market closes. This information comes directly from the company and was also shared through GlobeNewswire, although the latter is just a copy of the company's announcement, not an independent confirmation. This information was found on 2026-09-11 through a browser search. The scheduled release date is based on old information and does not guarantee that there was no other important news before then, so the entire event session will be excluded. https://www.globenewswire.com/news-release/2022/05/31/2453659/0/en/Concentrix-Schedules-Release-of-Fiscal-Second-Quarter-2022-Financial-Results-and-Webcast-of-Investor-Conference-Call.html

The company CNXC announced on 2022-03-09 that it will release its earnings on 2022-03-29 after the market closes, which is known as AMC, or after market close, a time when trading has ended for the day. The information comes directly from the company, which is the most reliable source, and was also copied by GlobeNewswire, although this is just a repeat of what the company said, not an independent confirmation. This information was found on 2026-09-11 using a browser search. The scheduled date is based on old information from 2022 and does not guarantee that there was no other important news before then, so the entire event on that day should be ignored. https://ir.concentrix.com/news/news-details/2022/Concentrix-Schedules-Release-of-Fiscal-First-Quarter-2022-Financial-Results-and-Webcast-of-Investor-Conference-Call-03-09-2022/default.aspx

The company CNXC announced on December 29, 2021, that it will release its earnings on January 18, 2022, after the market closes, which is known as AMC, or after market close, a time when the market is not open. The information comes directly from the company, which scheduled its own release, and was also copied by GlobeNewswire, but this copy is not an independent confirmation. This information was found on September 11, 2026, through a browser search, and the scheduled date is based on old information, not a complete proof that there was no other important news before, so the entire event session will be excluded. https://ir.concentrix.com/news/news-details/2021/Concentrix-Schedules-Release-of-Fourth-Quarter-and-Full-Year-Fiscal-2021-Financial-Results-and-Webcast-of-Investor-Conference-Call-12-29-2021/default.aspx

The company CNXC announced on 2021-09-07 that it will release its earnings on 2021-09-27 after the market closes, which is known as AMC, or after market close, a time when trading has ended for the day. The information comes directly from the company, which is the most reliable source, and was also copied on GlobeNewswire, although this is just a repeat of what the company said, not a separate confirmation. This information was found on 2026-09-11 using a browser search. The scheduled release date is based on old information from 2021 and does not guarantee that there was no other important news before then. The entire event on the day of the release should be ignored. https://ir.concentrix.com/news/news-details/2021/Concentrix-Schedules-Release-of-Fiscal-Third-Quarter-2021-Financial-Results-and-Webcast-of-Investor-Conference-Call-09-07-2021/default.aspx

The company CNXC announced on 2021-06-03 that it will release its earnings on 2021-06-23 after the market closes. This information comes directly from the company and was also copied on GlobeNewswire, but the copy is not an independent confirmation. This information was found on 2021-06-11 through a browser search. The scheduled release date is based on old information and does not guarantee that there was no other important news before then, so the entire event should be excluded. https://ir.concentrix.com/news-releases/news-release-details/concentrix-schedules-release-fiscal-second-quarter-2021/

The company CNXC announced on 2021-03-04 that it will release its earnings on 2021-03-24 after the market closes, which is known as AMC, or after market close, a time when the stock market is no longer open. The information came directly from the company, and was also found on GlobeNewswire, which was simply copying the company's announcement, not verifying it independently. This information was found on 2026-09-11 through a browser search. The scheduled date is based on old information from 2021, and does not guarantee that there was no other important news before then, so the entire event on that day should be ignored. https://ir.concentrix.com/news/news-details/2021/Concentrix-Schedules-Release-of-Fiscal-First-Quarter-2021-Financial-Results-and-Webcast-of-Investor-Conference-Call-03-04-2021/default.aspx

A news scan found the data line: holdout mean percentage is -0.7069703458888735, mean 95 percent confidence interval is between -2.4001668335274973 and 1.1512433681261125, sample size is 74, training probability is 0.1791044776119403, clinical risk difference percentage points is 60.7, and clinical approximate 95 percent confidence interval percentage points is between 50.61704621821972 and 70.78295378178028, this is from an iid bootstrap with 20000 iterations and seed 912, using clinical Wald from rounded rates, not FDA inference. https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT03573401

A news scan found the following data line for BFRI BFRI911 computed cash: net working capital source is 2.1609999999999996, pre working capital cash flow is -3.8889999999999993, cash flow excluding related paydown is 1.986, third party accounts payable source is 2.461, cash flow excluding both accounts payable changes is -0.47499999999999987, monthly pre working capital burn is 0.6481666666666666, cash months pre working capital is 7.187966058112626, cash months reported is 16.177083333333332, current ratio is 1.1796793473105018, earnout at 65 is 7.8, earnout at 65 01 is 9.7515, earnout step is 1.9515000000000002, and revenue required offset step is 2.5344155844155845. https://www.sec.gov/Archives/edgar/data/1858685/000149315226037834/form10-q.htm

A data scan found the following backtest results for BFRI BFRI911: the results are presented in a list of four sets of data, each representing a different test scenario. The first scenario, with a window called train and slippage of 25 basis points, had a return of -96.86978389282203 percent, a drawdown of 97.23930879674035 percent, and a win rate of 17.91044776119403 percent, based on 134 samples. The second scenario, also with a train window but with slippage of 45 basis points, had a return of -98.1685732622006 percent, a drawdown of 98.34604521965086 percent, and the same win rate, based on the same number of samples. The third scenario, with a window called holdout and slippage of 25 basis points, had a return of -52.212330001396104 percent, a drawdown of 74.97120068315613 percent, and a win rate of 29.72972972972973 percent, based on 74 samples. The fourth scenario, with a holdout window and slippage of 45 basis points, had a return of -64.45626423131446 percent, a drawdown of 79.87362001939641 percent, and a win rate of 28.37837837837838 percent, also based on 74 samples. https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=BFRI&feed=sip&adjustment=all

A news scan found the following data for BFRI: it has 1176 bars, the last update was on 2026-09-10 04:00:00+00:00, the close price is 1.46. The Simple Moving Average, or SMA, which is a calculation to smooth out price data over a certain period, for 20 days is 1.4787499999999998, for 50 days is 1.2745, and for 200 days is 0.9915795. The Relative Strength Index, or RSI, which measures the speed and change of price movements over 14 days is 53.44311231206737. The Average Daily Range, or ADR, which is the average price range over 20 days is 0.11005500000000001. The Average True Range, or ATR, which measures the volatility of an asset over 14 days is 0.10702857142857146. The return over 20 days is 16.799999999999994 percent. The average volume over 20 days is 737403.75, and the average dollar volume is 1079662.7682500002. The Realized Volatility, or RV, which measures the actual price fluctuations over 20 days is 55.823505088018265 percent. The worst gap percentage, which is the largest percentage difference between two consecutive prices, is -21.739130434782606 percent. https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=BFRI&feed=sip&adjustment=all

On June 30, the anti-dilutive vector, which is a way to calculate the total number of shares, excluded warrants, options, and other securities. The total number of warrants was 2,269,356, options was 3,095,468, unit options was 20,182, B preferred shares was 11,795,724, C shares was 15,533,724, D shares was 4,831,185, and notes was 6,009,921, totaling 43,555,560. By July 8, 552,483 B conversions had already occurred, and by August 11, there were 14,852,359 common shares, but we should avoid double counting. The clinical registry includes adult patients with a specific type of skin cancer, called BCC, who are non-aggressive and have a tumor size of around 20 square centimeters. This does not represent the entire BCC market. In the clinical trial, 3 out of 145 patients experienced serious side effects, compared to 2 out of 42 patients in the control group, and there were no deaths in either group. Additionally, 145 out of 145 patients experienced other side effects, compared to 35 out of 42 patients in the control group, but not all of these side effects were caused by the drug. The sponsor's registry data is shared with the issuer's clinical claims. https://www.sec.gov/Archives/edgar/data/1858685/000149315226037834/form10-q.htm ; https://clinicaltrials.gov/api/v2/studies/NCT03573401

A news scan found the headline 'BFRI BFRI911 full operative LEO and Inc CDO recovered' on September 11. This is about an outstanding order from May 6. It says that certain parts, like illuminators, panels, and a chemical called 5-ALA, are covered when used together, except for service or repair parts and warranty replacements. A document called Inc CDO, pages 21 to 28, defines what articles are covered and says sales, imports, and marketing are not allowed, with some exceptions. This resolves a notice about the wording of an oil vaporizer by specifying the instrument. The exceptions do not mean that a product called Ameluz can be freely supplied for a device called XL. Not all old PDT devices are banned, but the number of devices still in use has not been determined. https://www.usitc.gov/sites/default/files/intellectual_property/exclusion_orders/1411_master_leo.pdf

An agency originally issued and voted on September 1, filed on September 3 at 08:45, and published on September 4, that the International Trade Commission, or ITC, granted a request from Sun to lift a partial enforcement suspension related to the 028 patent, following a July 29 Director vacatur, which is a decision to cancel or annul something. This supersedes the suspension state from May 6 and the August 13 Management's Discussion and Analysis, or MD&A. This information is new to this update, but not new today. The document narrative has a typo in the chronology, erroneously dating an earlier FID to September 30, 2026, when the May notice and 10Q say September 30, 2025. However, this typo does not change the operative determination made on September 1. There is no appeal stay or Customs and Border Protection, or CBP, clearance that has been verified. https://public-inspection.federalregister.gov/2026-18101.pdf

On August 13, a note was made about a request to redesign the ruling for Customs, which was submitted on June 4, but no ruling has been made as of the filing date. A response is expected in September or October 2026, although this deadline is not confirmed. On July 29, the USPTO Director vacated a decision from February 23 that found a patent to be unpatentable, and this decision was dismissed. The company may appeal this decision. A suspension from the ITC on May 6 does not guarantee current blanket protection. The note explicitly states that the legacy BF-Rhodo LED Ameluz is unaffected, and associated drug imports and sales ceased after July 6. The company has a minimum annual manufacture or order of 80,000 tubes starting from 2026, and if there are two consecutive failures, the assets may be reverted. Management claims they are on track, but this is not based on actual orders. The company forecasts 100kg of API through Q2 2028, but this forecast is non-binding. As of 04 UTC, there were no subsequent 8K submissions to the SEC after August 13, but the absence of a submission does not prove or disprove a ruling. https://www.sec.gov/Archives/edgar/data/1858685/000149315226037834/form10-q.htm

A news scan found the headline 'BFRI BFRI911 Registered sBCC primary endpoint and comparator'. Retrieved on September 11, a sponsor-reported registry of 187 patients, with 145 active and 42 in the vehicle group, showed clinical and histological main lesion clearance 12 weeks after the last PDT cycle of 65.5% compared to 4.8%. Clinical clearance was 83.4% compared to 21.4%, and histological clearance was 75.9% compared to 19.0%. The first PDT cycle composite was 44.1% compared to 2.4%. The BF-RhodoLED was used, and it did not require XL in the protocol. These results were first posted on April 29, 2025, and last updated on January 14, 2026. This is not new data, and it is not a comparison with surgery or other active care, and it does not indicate approval probability. https://clinicaltrials.gov/api/v2/studies/NCT03573401

The terms for BFRI, as of June 30, include an earnout for Ameluz US annual revenue, which is 12% for revenue less than or equal to $65 million and 15% for revenue greater than $65 million, according to the Management's Discussion and Analysis. The notes have a principal remaining of $4 million at a conversion price of $0.78, resulting in 5,128,205 shares, excluding Payment in Kind, or PIK, which is a type of interest payment. The PIK is 10% and matures in November 2022, with a maturity date of 2027, and is secured by assets. The notes will automatically convert if the 10-day volume-weighted average price, or VWAP, is greater than 250% of the conversion price, plus other conditions. There are also warrants, which are options to buy stock, totaling 2,269,356, with 2,192,736 having a strike price of $3.55 and 76,620 having a strike price of $100. The preferred stock has a ratio of 1413 for B2 and 6498 for B3, and 1600.26 for C9707 and D3019 per conversion, which means the number of shares of common stock received upon conversion. This conversion does not result in new cash, but rather dilution of existing shares. As of August 11, there were 14,852,359 common shares. The remediation total is $0.5 million, which includes a $0.1 million inventory write-off and a $0.4 million accrual, with a range of $0.4 to $0.6 million. The regulatory path and cost are unknown. There is also a $1 million milestone payment contingent on Xepi, which is not in cash, as of December 1. https://www.sec.gov/Archives/edgar/data/1858685/000149315226037834/form10-q.htm

A financial report from August 13 for the period ending June 30 was released on September 11. The report showed a net loss of 5.356 million US dollars. This loss included non-cash items such as depreciation and amortization of 0.120 million US dollars, right of use assets of 0.263 million US dollars, stock-based compensation of 0.605 million US dollars, interest of 0.259 million US dollars, credit of 0.040 million US dollars, warrants of 0.175 million US dollars, investment of 0.001 million US dollars, and lease of 0.004 million US dollars. The report also showed changes in working capital, including an increase in accounts receivable of 1.706 million US dollars, a decrease in related party receivables of 0.054 million US dollars, an increase in prepaid expenses of 1.296 million US dollars, an increase in related assets of 0.452 million US dollars, an increase in inventory of 0.386 million US dollars, an increase in accounts payable of 2.461 million US dollars, a decrease in related party accounts payable of 3.714 million US dollars, a decrease in lease liabilities of 0.184 million US dollars, and a decrease in accruals of 0.188 million US dollars. The report showed that cash flow from operations was -1.728 million US dollars, capital expenditures were -0.005 million US dollars, and there was no financing activity. The company had 4.659 million US dollars in unrestricted cash and 0.200 million US dollars in restricted cash. The report also showed that current assets were 12.435 million US dollars and current liabilities were 10.541 million US dollars. These numbers represent the cash flow for the first half of the year and do not represent the current run rate. https://www.sec.gov/Archives/edgar/data/1858685/000149315226037834/form10-q.htm

On May 6, an agency notice, 337-TA-1411, found a violation related to LEO/CDOs. The notice covers infringing PDT systems, components, and a specific drug combination. As a result, patent 028 has been suspended pending a review by the Board or appeals, but this is not a complete stop. The first page of the notice mentions oil vaporizing devices, which seems to be a mistake in the template used. Because of this, it is not clear what exactly is covered by the notice, so the full orders are needed to understand it. The issuer's 10Q report states that imports and sales of XL and Ameluz for XL are restricted. A release says this restriction is effective July 7, but most of the installed base is not affected. It is important to separate the agency's original decision from the issuer's commercial interpretation. https://www.usitc.gov/system/files/secretary/fed_reg_notices/337/337_1411_notice05062026sgl_0.pdf

A news scan found the headline about BFRI and BFRI911. On May 14, the issuer set September 28, 2026, as the sBCC PDUFA date, which is the date the US Food and Drug Administration will decide on approval, PDUFA stands for Prescription Drug User Fee Act. On August 13, a release retained a late September and conditional Q1 2027 launch. The pipeline includes AK extremities, neck, and trunk in Phase 3, which is the last stage of testing before approval, and acne in Phase 2b, which is a stage of testing that looks for effectiveness. No exact new readout date, which is the date when results are announced, has been verified. This information was retrieved on September 11 at 04 UTC, which is a time zone. The date-only target is not guaranteed to be the first news about this topic. https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm